CC-671

SKU: orb1302822

Description

CC-671 is a potent and selective small molecule inhibitor targeting both TTK (IC50: 5 nM) and CLK2 (IC50: 6 nM) kinases. It is a valuable research tool for investigating cell cycle regulation and pre-mRNA splicing in vitro, with studies exploring its potential in cancer research models.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 1618658-88-0
• MW: 512.56
• Purity: 98.80% (May vary between batches)
• Formula: C₂₈H₂₈N₆O₄
• SMILES: CNC(=O)c1ccc(Nc2nc(OC3CCCC3)c3c(c[nH]c3n2)-c2ccc3nc(C)oc3c2)c(OC)c1
• Target: CDK,Tyrosine Kinases
• Solubility: DMSO:50 mg/mL (97.55 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.9 mM)

Bioactivity

• Target IC50:
  TTK:0.005 μM|CLK2:0.006 μM
• In Vivo:
  CC-671 significantly inhibits tumor growth by 71% at doses of both 10 and 20 mg/kg on an every 3 days (q3d) dosing schedule, with no difference in efficacy between the two doses. However, it induces greater body weight loss at 20 mg/kg compared to 10 mg/kg (17% vs 5%).
  Read more...
• In Vitro:
  HCT-116 cell lysates treated with CC-671 at 3 μM for 1 h demonstrates that only four kinases show cellular binding of 75% or more including CLK2, CAMKK2, PIP4K22, and JNK.
  Read more...
• Animal Research:
  Female SCID mice are inoculated subcutaneously with 5×106 Cal-51 cells. Mice with tumours of approximately 125 mm3 are randomized and treated intravenously at various doses and schedules of CC-671 (n=8 to10/group). Tumours are measured twice a week for the duration of the study. The long and short axes of each a tumour are measured using a digital calliper in millimetres and the tumour volumes are calculated.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CLK2, CDK, CC 671, CC-671, CC671, Cyclin dependent kinase, inhibit, Inhibitor, TTK

Compound Identifiers

PubChem CID

117881270